Please login to the form below

Not currently logged in
Email:
Password:

respiratory syncytial virus

This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.

Moderna launches phase 1/2 study of mRNA-based flu vaccine

Moderna launches phase 1/2 study of mRNA-based flu vaccine

The company is also planning to explore potential combination vaccines that protect against flu, SARS-CoV-2 (COVID-19), respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). ... Respiratory combination vaccines are an important pillar of

Latest news

More from news
Approximately 2 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Well-funded life sciences firms are making long-term progress – and their investors are too Well-funded life sciences firms are making long-term progress – and their investors are too

    Up to that point, the drug was being developed to treat respiratory viral infections in patients with COPD who are at risk of experiencing exacerbations, which can be deadly and typically ... challenge study, in this case respiratory syncytial virus (RSV)

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    In the absence of a knockout antiviral, researchers are trying to mitigate harmful effects of the virus. ... Scientists have since industrialised the concept, leading to the development of antibodies against Ebola and respiratory syncytial virus.

  • Getting multichannel marketing right Getting multichannel marketing right

    has encouraged people to knit hats and blankets for babies to alert people to respiratory syncytial virus.

  • Deal Watch March 2017 Deal Watch March 2017

    In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...